

Special Issue

Ophthalmic Genetics: Unraveling the Genomics of Eye Disorders

Message from the Guest Editor

The study of eye diseases is a rapidly evolving field that aims to understand the genetic basis of these conditions, ranging from common (glaucoma and age-related macular degeneration) to rare (retinitis pigmentosa and enhanced S-cone syndrome). By studying the genetic background of ocular disorders, researchers have been able to identify the molecular pathways that contribute to the onset and progression of disease. In addition, the introduction of genetic testing has enabled early diagnosis and the implementation of personalized treatment approaches. In this regard, the implementation of innovative tools (third generation sequencing and artificial intelligence technologies) has led to the more precise identification of pathogenic variants and enhanced gene therapy options. This knowledge has the potential to improve patient care and preventive strategies, and reduce the global burden of blindness and visual impairment.

Guest Editor

Dr. Raffaella Cascella

Genomic Medicine Laboratory UILDM, IRCCS Fondazione Santa Lucia,
Via Ardeatina 306-354, 00179 Rome, Italy

Deadline for manuscript submissions

31 May 2025



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 5.2
Indexed in PubMed



mdpi.com/si/223634

Biomedicines
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 5.2
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.3 days after submission; acceptance to publication is undertaken in 3.4 days (median values for papers published in this journal in the first half of 2024).